Massive hepatic apoptosis associated with TGF-β1 activation after Fas ligand treatment of IGF binding protein-1–deficient mice
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Acute liver failure caused by viral hepatitis or toxic damage involves both apoptotic and necrotic pathways. IGF binding protein-1 (IGFBP-1), a hepatocyte-derived secreted protein, is required for normal liver regeneration. To determine whether IGFBP-1 could prevent liver injury that entails direct stimulation of hepatocyte apoptosis, IGFBP-1(-/-) mice, IGFBP-1(+/+) mice, and mice pretreated with Ab's against IGFBP-1 were treated with a normally sublethal dose of Fas agonist. IGFBP-1 deficiency was associated with massive hepatocyte apoptosis and caspase activation within 3 hours of Fas agonist treatment, which could be corrected by pretreatment with IGFBP-1. IGFBP-1-deficient livers had enhanced signaling via the integrin receptor at early times (0.5 to 1 hour) after Fas agonist treatment accompanied by elevated activated matrix metalloproteinase-9 (MMP-9), a known target of fibronectin signaling and activator of TGF-beta. Within 3 hours of Fas agonist treatment, elevated expression of active TGF-beta1, a hepatocyte apoptogen, was observed in IGFBP-1-deficient livers that correlated with the appearance of the apoptotic process. Both MMP-9 and TGF-beta1 expression were suppressed by IGFBP-1 treatment, supporting their role in the apoptotic process. IGFBP-1(-/-) mice also displayed increased injury in a toxic hepatic injury model caused by CCl(4). These findings indicate that IGFBP-1 functions as a critical hepatic survival factor in the liver by reducing the level of proapoptotic signals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Giancotti, F. G., & Ruoslahti, E. (1999) · Science · doi:10.1126/science.285.5430.1028 · Cited by 3,869
Two CD95 (APO‐1/Fas) signaling pathways
Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K., Krammer, P. H., & Peter, M. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.6.1675 · Cited by 3,000
Lethal effect of the anti-Fas antibody in mice
Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., & Nagata, S. (1993) · Nature · doi:10.1038/364806a0 · Cited by 1,881 · cited 4×
“25 μg/g resulted in significant mortality in wild-type strains as well as in IGFBP-1– deficient strains (1, 19).”
BackgroundInfluentialYu, Q., & Stamenkovic, I. (2000) · Genes & Development · doi:10.1101/gad.14.2.163 · Cited by 1,754
Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins
Stupack, D. G., Puente, X. S., Boutsaboualoy, S., Storgard, C. M., & Cheresh, D. A. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200106070 · Cited by 554
Insulin-like Growth Factor Binding Protein-1: Recent Findings and New Directions
Lee, P. D. K., Giudice, L. C., Conover, C. A., & Powell, D. R. (1997) · Experimental Biology and Medicine · doi:10.3181/00379727-216-44182 · Cited by 523
Ilić, D., Almeida, E. A. C., Schlaepfer, D. D., Dazin, P., Aizawa, S., & Damsky, C. H. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.143.2.547 · Cited by 495
Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice
Kovalovich, K., DeAngelis, R. A., Li, W., Furth, E. E., Ciliberto, G., & Taub, R. (2000) · Hepatology · doi:10.1002/hep.510310123 · Cited by 298 · cited 2×
“Acute CCl4 injury, BrdU immunohistochemistry, and TUNEL staining were performed as described previously (24, 25).”
MethodSelf-citationGreenbaum, L. E., Li, W., Cressman, D. E., Peng, Y., Ciliberto, G., Poli, V, & Taub, R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3135 · Cited by 270
Self-citationLeu, J. I., Crissey, M. A. S., Leu, J. P., Ciliberto, G., & Taub, R. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.2.414-424.2001 · Cited by 134 · cited 4×
“Whole-cell extracts were prepared as previously described and subjected to Western analyses (5).”
BackgroundMethodSelf-citationLi, W., Liang, X., Leu, J. I., Kovalovich, K., Ciliberto, G., & Taub, R. (2001) · Hepatology · doi:10.1053/jhep.2001.24431 · Cited by 114
Self-citation
Cited by
Liver regeneration: from myth to mechanism
Taub, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1489 · Cited by 1,567
“Likewise, IGFBP1, another pro-regeneration factor, is highly protective against Fas-mediated injury that occurs by pathways other than those stimulated by IL-6 and STAT3 (Ref”
BackgroundSelf-citationMammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression
Song, H., Mak, K. K., Topol, L., Yun, K., Hu, J., Garrett, L., Chen, Y., Park, O., Chang, J., Simpson, R. M., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911409107 · Cited by 583
IGF binding proteins in cancer: mechanistic and clinical insights
Baxter, R. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3720 · Cited by 525
IGF-Binding Proteins: Why Do They Exist and Why Are There So Many?
Allard, J. B., & Duan, C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00117 · Cited by 515
Duan, C., Ren, H., & Gao, S. (2010) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2010.04.009 · Cited by 492
Metadata
- Authors
- Leu, J. I., Crissey, M. A. S., & Taub, R.
- Venue
- Journal of Clinical Investigation
- Published
- 2003-01-01
- Volume
- 111
- Issue
- 1
- Pages
- 129-139
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2109375797
- Cited by
- 128
- References
- 11
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.